2023
Exploring anxiety as an influencing factor of the impact of exercise and mind-body prehabilitation on cognitive functioning among women undergoing breast cancer surgery
Knoerl R, Sannes T, Giobbie-Hurder A, Frank E, McTiernan A, Winer E, Irwin M, Ligibel J. Exploring anxiety as an influencing factor of the impact of exercise and mind-body prehabilitation on cognitive functioning among women undergoing breast cancer surgery. Journal Of Psychosocial Oncology 2023, 42: 448-456. PMID: 38044630, DOI: 10.1080/07347332.2023.2282021.Peer-Reviewed Original ResearchCognitive functioningWorse cognitive functioningBreast cancer surgerySelf-report measuresTime of diagnosisAssessment of anxietyBreast cancerCancer surgeryCognitive functionGreater anxietyAnxiety managementPrehabilitation interventionsAnxietyLinear modelingFunctioningSignificant anxietyAcademic cancer centerImpact of exerciseImpact of baselinePrevalence of anxietyParticipantsOne-unit decreaseStudy enrollmentLinear regression modelingCancer Center
2021
Exploring the impact of exercise and mind–body prehabilitation interventions on physical and psychological outcomes in women undergoing breast cancer surgery
Knoerl R, Giobbie-Hurder A, Sannes TS, Chagpar AB, Dillon D, Dominici LS, Frank ES, Golshan M, McTiernan A, Rhei E, Tolaney SM, Winer EP, Yung RL, Irwin ML, Ligibel JA. Exploring the impact of exercise and mind–body prehabilitation interventions on physical and psychological outcomes in women undergoing breast cancer surgery. Supportive Care In Cancer 2021, 30: 2027-2036. PMID: 34648061, DOI: 10.1007/s00520-021-06617-8.Peer-Reviewed Original ResearchConceptsCancer treatment-related symptomsPrehabilitation interventionsTreatment-related symptomsTime of enrollmentImpact of exerciseQuality of lifeBreast cancerGroup participantsPre-operative exerciseBreast cancer surgeryMind-body interventionsCognitive functioningOpportunity trialCancer surgeryOutcome measuresSecondary analysisOne monthSurgeryMeasures of qualityGroup comparisonsCancer diagnosisCancerWomenInterventionSignificant differences
2020
De-escalating Breast Cancer Surgery—Where Is the Tipping Point?
Morrow M, Winer EP. De-escalating Breast Cancer Surgery—Where Is the Tipping Point? JAMA Oncology 2020, 6: 183-184. PMID: 31830209, DOI: 10.1001/jamaoncol.2019.4849.Peer-Reviewed Original ResearchConceptsIncidence of surgeryBreast cancer surgeryCancer surgeryRecent trialsBreast cancerSurgeryCancerIncidenceTrials
2010
Does Neoadjuvant Bevacizumab Increase Surgical Complications in Breast Surgery?
Golshan M, Garber JE, Gelman R, Tung N, Smith BL, Troyan S, Greenberg CC, Winer EP, Ryan P. Does Neoadjuvant Bevacizumab Increase Surgical Complications in Breast Surgery? Annals Of Surgical Oncology 2010, 18: 733-737. PMID: 20882415, DOI: 10.1245/s10434-010-1366-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabBreast NeoplasmsChemotherapy, AdjuvantCisplatinCombined Modality TherapyFemaleHumansMiddle AgedNeoadjuvant TherapyNeoplasm Recurrence, LocalNeoplasm StagingPostoperative ComplicationsReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneSentinel Lymph Node BiopsySurvival RateTreatment OutcomeConceptsTriple-negative breast cancerSingle-arm trialNeoadjuvant cisplatinPostoperative complicationsBreast cancerTwo-sided Fisher's exact testExpander/implantsSafety of bevacizumabOperable breast cancerDefinitive local therapyBreast cancer surgeryNegative breast cancerFisher's exact testBackgroundNeoadjuvant chemotherapyNeoadjuvant settingNeoadjuvant therapyProtocol therapySurgical complicationsLocal therapyRelated complicationsCancer surgeryCisplatin therapyBreast surgeryComplicationsPatients
2009
Surgical Complications and the Use of Neoadjuvant Bevacizumab.
Golshan M, Garber J, Gelman R, Tung N, Smith B, Troyan S, Greenberg C, Winer E, Ryan P. Surgical Complications and the Use of Neoadjuvant Bevacizumab. Cancer Research 2009, 69: 43-43. DOI: 10.1158/0008-5472.sabcs-09-43.Peer-Reviewed Original ResearchTriple-negative breast cancerDefinitive local therapyPhase II trialPostoperative complicationsNeoadjuvant cisplatinDefinitive surgeryII trialWound breakdownLocal therapyMedian ageBreast cancerSingle-arm phase II trialArm phase II trialTwo-sided Fisher's exact testClinical stage IIDose-dense ACSafety of bevacizumabOperable breast cancerBreast cancer surgerySingle-arm trialNegative breast cancerFisher's exact testCycles cisplatinNeoadjuvant bevacizumabNeoadjuvant settingRacial Differences in Definitive Breast Cancer Therapy in Older Women
Keating NL, Kouri E, He Y, Weeks JC, Winer EP. Racial Differences in Definitive Breast Cancer Therapy in Older Women. Medical Care 2009, 47: 765-773. PMID: 19536008, DOI: 10.1097/mlr.0b013e31819e1fe7.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedBlack or African AmericanBreast NeoplasmsChi-Square DistributionFemaleHealth Services ResearchHealthcare DisparitiesHospitalsHumansLogistic ModelsMastectomyMedicareMultivariate AnalysisPractice Patterns, Physicians'Quality of Health CareSEER ProgramSensitivity and SpecificitySocioeconomic FactorsUnited StatesWhite PeopleConceptsHigh-volume hospitalsDefinitive primary therapyHigh-quality hospitalsBreast-conserving surgeryBreast cancer therapyBreast cancerPrimary therapyWhite womenRacial disparitiesStage I/II breast cancerBlack womenPrimary breast cancer therapyEarly-stage breast cancerLow-volume hospitalsBreast cancer patientsBreast cancer surgeryPatterns of careSEER-Medicare databaseCancer therapyPopulation-based sampleOlder Black womenDefinitive therapyVolume hospitalsCancer surgeryCancer patients